Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Verve Group

    MCap

    EUR692m

    Last close

    EUR3.71

    ▲ 0.64 (20.85%)

    OSE Immunotherapeutics

    MCap

    EUR158m

    Last close

    EUR7.24

    ▲ 0.66 (10.03%)

    Amoeba

    MCap

    EUR26m

    Last close

    EUR0.52

    ▲ 0.04 (8.33%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BB Biotech (BION)

Last close As at 18/09/2024

CHF37.55

▲ −0.05 (−0.13%)

Market capitalisation

CHF2,081m

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

Latest Insights

View More

Investment Companies | Update

BB Biotech — Lower rates and news flow to support recovery

Investment Companies | Flash note

BB Biotech — Positive trial news lifts two portfolio holdings

edison tv

Edison Growth Conference panel – 2024: The year of M&A?

Investment Companies | Review

BB Biotech — A recovering sector with a healthy prognosis
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
Visit Website

Equity Analyst

Joanne Collins

Joanne Collins

Analyst, Investment Trusts

Key Management

  • Claude Mikkelsen

    Director of IR

  • Daniel Koller

    Head of investment management

  • Dr Silvia Siegfried-Schanz

    Director of IR

  • Erich Hunziker

    Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.5) (4.1) (14.2)
Relative (5.3) (4.4) (20.2)
52 week high/low CHF49.4/CHF35.6

Overview

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. The company recently released its interim report for the period ended 30 June 2024, which provided an update on recent performance and developments with portfolio companies, and outlined the major milestones expected from these holdings during the second half of 2024. This note summarises the key points from the report, and the reasons why BION’s managers are optimistic about the outlook for the biotech sector and for their portfolio.

Research

Flash note

Investment Companies

BB Biotech — Positive trial news lifts two portfolio holdings

edison tv

Edison Growth Conference panel – 2024: The year of M&A?

Investment Companies

Update

BB Biotech — Lower rates and news flow to support recovery

Review

Investment Companies

BB Biotech — A recovering sector with a healthy prognosis
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Update

Investment Companies

BB Biotech — A cutting-edge sector and a high dividend
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Update

Investment Companies

BB Biotech — Picking growth at good value

edison tv

Investment Companies

BB Biotech – executive interview

Review

Investment Companies

BB Biotech — Great valuation potential

edison tv

Investment Companies

BB Biotech – executive interview

edison tv

Investment Companies

BB Biotech – fund manager interview

Review

Investment Companies

BB Biotech — RNA focus provides a possible COVID-19 solution
View All

Thematics

thematic

Investment Companies

Vietnam Holding – Vietnam in the global digital race

thematic

Investment Companies

US small-cap equities – Time to shine?

thematic

Investment Companies

Emerging markets – Worthy of consideration

thematic

Investment Companies

Dynam Capital at the 2024 Vietnam ESG Conference
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free